Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11807010 | 0.98 | NPSR1 (0.44) | NPSR1RAB9AALDH1A1POLBHPGD | |
| SCHEMBL11806820 | 0.91 | NPSR1 (0.35) | NPSR1RAB9AALDH1A1POLBMAPT | |
| SCHEMBL2957126 | 0.75 | NPSR1 (0.45) | NPSR1RAB9AALDH1A1POLBHPGD | |
| SCHEMBL1544893 | 0.73 | ALDH1A1 (0.46) | ALDH1A1POLBHPGDMAPT | |
| SCHEMBL19281550 | 0.73 | HSD11B1 (0.33) | ALDH1A1HPGD | |
| SCHEMBL19520381 | 0.72 | SMN1; SMN2 (0.50) | NPSR1ALDH1A1POLBHPGD | |
| SCHEMBL11721146 | 0.72 | ATM (0.37) | ATM | |
| SCHEMBL390783 | 0.71 | ALDH1A1 (0.41) | ALDH1A1HPGDMAPTHSD17B10 | |
| SCHEMBL10965169 | 0.69 | ATM (0.32) | ATM | |
| SCHEMBL19281543 | 0.69 | HSD11B1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20050096320-A1 | Triazolotriazinones and the use thereof | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1261609-B1 | TRIAZOLOTRIAZINONES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6683081-B2 | INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOPHATE METABOLIZING PHOSPHODIESTERASES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
| US-6683081-B2 | INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOPHATE METABOLIZING PHOSPHODIESTERASES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
| US-6683081-B2 | INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOPHATE METABOLIZING PHOSPHODIESTERASES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-27 | — | — | US | disclosed |
| US-20030212064-A1 | Triazolotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | US | disclosed |
| EP-1261609-A1 | TRIAZOLOTRIAZINONES AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001047929-A1 | TRIAZOLOTRIAZINONES AND THE USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096320-A1 | Triazolotriazinones and the use thereof | CYP3A5, CYP3A7, CYP51A1 | NPSR1 1209/4885RAB9A 3881/4885ALDH1A1 2303/4885 |
| US-20030212064-A1 | Triazolotriazinones and the use thereof | CYP3A5, CYP3A7, CYP51A1 | NPSR1 994/4885RAB9A 3921/4885ALDH1A1 1586/4885 |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | NPSR1 2961/4885RAB9A 3002/4885ALDH1A1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.